The Ketogenic Diet Including Breast Milk for Treatment of Infants with Severe Childhood Epilepsy: Feasibility, Safety, and Effectiveness

被引:15
|
作者
Dressler, Anastasia [1 ]
Haefele, Chiara [1 ]
Giordano, Vito [1 ]
Benninger, Franz [2 ]
Trimmel-Schwahofer, Petra [1 ]
Groeppel, Gudrun [1 ]
Samueli, Sharon [1 ]
Feucht, Martha [1 ]
Male, Christoph [1 ]
Repa, Andreas [1 ]
机构
[1] Med Univ Vienna, Dept Pediat & Adolescent Med, Waehringer Guertel 18-20, A-1090 Vienna, Austria
[2] Med Univ Vienna, Dept Child & Adolescent Neuropsychiat, Vienna, Austria
关键词
ketogenic diet; breast milk; infants; epilepsy; beta-hydroxybutyrate; ASSOCIATION;
D O I
10.1089/bfm.2019.0190
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: The ketogenic diet (KD) is a high-fat and restricted carbohydrate diet for treating severe childhood epilepsy. In infants, breast milk is usually fully replaced by a ketogenic formula. At our center, mothers are encouraged to include breastfeeding into the KD if still breastfeeding. This retrospective study describes achievement and maintenance of ketosis with or without inclusion of breast milk. Methods: Data were retrieved from a prospective longitudinal database of children treated with KD for epilepsy analyzing infants <1 year of age. The time to achieve clinically relevant ketosis (>= 2 mmol/L beta-hydroxybutyrate) was compared with and without inclusion of breast milk into standard KD. Ketosis, nutritional intakes, effectiveness, adverse effects, and successful continuation of breastfeeding were evaluated. Results: A total of 79 infants were eligible for analysis. In 20% (16), breast milk was included. Infants with breast milk included into the KD achieved relevant ketosis in 47 hours (interquartile range [IQR] 24-95) compared with 41 hours (IQR 22-70; p = 0.779) in infants with standard KD. Beta-hydroxybutyrate at day 2 was 3.1 mmol/L (IQR 0.5-4.9) and 3.8 mmol/L (IQR 2.2-4.9). Infants with breast milk included received higher amounts of carbohydrates at baseline and calories at 3 months. Seizure freedom and adverse effects showed no relevant differences. No infections occurred in infants receiving breast milk. In two infants, KD was initiated with breast-feds after bottle-feeding KD formula. In 31%, breastfeeding was continued after the KD, and in 25%, inclusion of breast milk and breastfeeding was maintained until complete weaning. Before discharge from hospital, the amount of breast milk included was median 90 mL/day (IQR 53-203) equivalent to median 9% (IQR 6-15). Conclusions: Appropriate ketosis was achieved in most infants and maintained within 48 hours. Incorporation of breast milk into KD is feasible, safe, and effective.
引用
收藏
页码:72 / 78
页数:7
相关论文
共 45 条
  • [31] The relation of etiology based on the 2017 ILAE classification to the effectiveness of the ketogenic diet in drug-resistant epilepsy in childhood
    Breu, Markus
    Haefele, Chiara
    Trimmel-Schwahofer, Petra
    Schmidt, Wolfgang M.
    Laconne, Franco
    Vodopiutz, Julia
    Male, Christoph
    Dressler, Anastasia
    EPILEPSIA, 2021, 62 (11) : 2814 - 2825
  • [32] Efficacy and safety of a smartphone application-based treatment of ketogenic diet in pediatric refractory epilepsy
    Li, Wei
    Gu, Wei
    Liang, Chao
    Tu, Fulai
    Ding, Le
    Lu, Xiaopeng
    Guo, Hu
    Zheng, Guo
    Wu, Chunfeng
    EPILEPSIA OPEN, 2024, 9 (01) : 278 - 286
  • [33] Ketogenic diet treatment in recurrent diffuse intrinsic pontine glioma in children: A safety and feasibility study
    van der Louw, Elles J. T. M.
    Reddingius, Roel E.
    Olieman, Joanne F.
    Neuteboom, Rinze F.
    Catsman-Berrevoets, Coriene E.
    PEDIATRIC BLOOD & CANCER, 2019, 66 (03)
  • [34] Efficacy of the Ketogenic Diet for the Treatment of Refractory Childhood Epilepsy: Cerebrospinal Fluid Neurotransmitters and Amino Acid Levels
    Sariego-Jamardo, Andrea
    Garcia-Cazorla, Angels
    Artuch, Rafael
    Castejon, Esperanza
    Garcia-Arenas, Dolores
    Molero-Luis, Marta
    Ormazabal, Aida
    Xavier Sanmarti, Francesc
    PEDIATRIC NEUROLOGY, 2015, 53 (05) : 422 - 426
  • [35] Comment on: Ketogenic diet treatment in recurrent diffuse intrinsic pontine glioma in children: A safety and feasibility study
    Perez, Alexandre
    Merlini, Laura
    El-Ayadi, Moatasem
    Korff, Christian
    Ansari, Marc
    von Bueren, Andre O.
    PEDIATRIC BLOOD & CANCER, 2019, 66 (07)
  • [36] Ketogenic diet treatment in diffuse intrinsic pontine glioma in children: Retrospective analysis of feasibility, safety, and survival data
    Perez, Alexandre
    van der Louw, Elles
    Nathan, Janak
    El-Ayadi, Moatasem
    Golay, Hadrien
    Korff, Christian
    Ansari, Marc
    Catsman-Berrevoets, Coriene
    von Bueren, Andre O.
    CANCER REPORTS, 2021, 4 (05)
  • [37] Long-term effectiveness and adverse effects of ketogenic diet therapy in infants with drug-resistant epilepsy treated at a single center in Argentina
    Armeno, Marisa
    Verini, Antonella
    Caballero, Eugenia
    Cresta, Araceli
    Reyes Valenzuela, Gabriela
    Caraballo, Roberto
    EPILEPSY RESEARCH, 2021, 178
  • [38] The MCT-ketogenic diet as a treatment option in refractory childhood epilepsy: A prospective study with 2-year follow-up
    Lambrechts, Danielle A. J. E.
    de Kinderen, Reina J. A.
    Vles, Hans S. H.
    de Louw, Anton J.
    Aldenkamp, Albert P.
    Majoie, Marian J. M.
    EPILEPSY & BEHAVIOR, 2015, 51 : 261 - 266
  • [39] The Acceptability, Feasibility, and Effectiveness of Breast Massage Combined with Acupoint Stimulation to Promote the Volume of Human Milk in Mothers with Preterm Infants: A Pilot Study
    Sheng, Jia
    Ding, Yan
    Wang, Jing
    Zhang, Junping
    Qi, Xingling
    Xia, Haiou
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2021, 2021
  • [40] Problems associated with a highly artificial ketogenic diet: Letter to the Editor Re: van der Louw EJTM, Olieman JF, van den Bemt PMLA, et al. 'Ketogenic diet treatment as adjuvant to standard treatment of glioblastoma multiforme: a feasibility and safety study'
    Klement, Rainer Johannes
    Sweeney, Reinhart A.
    Gross, Elena C.
    Champ, Colin E.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11